Dostarlimab

2024: Creating a Cure

A new cancer drug has been developed in Russia, which has shown 100% effectiveness in clinical trials. Dostarlimab has demonstrated complete remission in all patients, which confirms its potential in the fight against cancer. This became known in mid-June 2024.

According to the publication, Dostarlimab, an inhibitor of immune checkpoints, aims to block the PD-1 protein, which prevents T cells from attacking and destroying tumor cells. This mechanism allows the drug to have minimal effects on healthy cells, which contributes to better tolerability compared to conventional chemotherapy.

Unsplash

According to the newspaper, during clinical trials conducted in Russia, Dostarlimab showed 100% remission in patients with rectal cancer. Within 26 months of follow-up after treatment, they showed no signs of tumor.

Many types of tumors activate special molecules in the cells of organisms - immune checkpoints. As a result, the tumor is protected from attack by immune cells. To solve this problem, immune checkpoint inhibitors (ICTIs, including Dostarlimab) have been developed. They block checkpoints, restoring the ability of the immune system to destroy cancer, "said Natalia Pashchenko, oncologist from the Center for Molecular Diagnostics (CMD) in Ramenskoye, FBUN of the Central Research Institute of Epidemiology of Rospotrebnadzor.

Despite the impressive results, Dostarlimab is not yet included in the standard clinical guidelines for oncology, she said. Final conclusions about the efficacy and safety of Dostarlimab will be made only after the completion of all phases of clinical trials. Currently, the drug continues to undergo the necessary tests and studies.^[1]

Notes